India Markets open in 6 hrs 32 mins
  • BSE SENSEX

    44,149.72
    -109.98 (-0.25%)
     
  • Nifty 50

    12,968.95
    -18.05 (-0.14%)
     
  • Dow

    29,638.64
    -271.73 (-0.91%)
     
  • Nasdaq

    12,198.74
    -7.11 (-0.06%)
     
  • BTC-INR

    1,438,703.62
    +3,419.00 (+0.24%)
     
  • CMC Crypto 200

    381.87
    +17.27 (+4.74%)
     
  • Hang Seng

    26,341.49
    -553.19 (-2.06%)
     
  • Nikkei

    26,433.62
    -211.09 (-0.79%)
     
  • EUR/INR

    88.3137
    -0.1528 (-0.17%)
     
  • GBP/INR

    98.6105
    +0.1953 (+0.20%)
     
  • AED/INR

    20.1050
    +0.0240 (+0.12%)
     
  • INR/JPY

    1.4078
    +0.0024 (+0.17%)
     
  • SGD/INR

    55.1900
    -0.0430 (-0.08%)
     

Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

Liquidia Technologies, Inc.
·1-min read

Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that third quarter 2020 financial results will be reported on Friday, November 6, 2020. The company will host a webcast and conference call on Monday, November 9, 2020 at 8:00 a.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7617005. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com